Fluticasone propionate

Generic Name
Fluticasone propionate
Brand Names
Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
Drug Type
Small Molecule
Chemical Formula
C25H31F3O5S
CAS Number
80474-14-2
Unique Ingredient Identifier
O2GMZ0LF5W
Background

Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication

Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions
Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
Associated Therapies
-
Clinical Trials
Related News

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

First Posted Date
2020-10-23
Last Posted Date
2023-10-31
Lead Sponsor
St. Paul's Sinus Centre
Registration Number
NCT04601324

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

Phase 3
Completed
Conditions
Perennial Allergic Rhinitis
Interventions
Drug: Fluticasone Propionate
First Posted Date
2020-04-03
Last Posted Date
2020-04-08
Lead Sponsor
Libbs Farmacêutica LTDA
Target Recruit Count
566
Registration Number
NCT04332978

Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis

First Posted Date
2020-01-27
Last Posted Date
2021-03-18
Lead Sponsor
Stanford University
Registration Number
NCT04242368
Locations
🇺🇸

Stanford University, Stanford, California, United States

Personalized Treatment Algorithms for Difficult-to-treat Asthma

First Posted Date
2019-11-27
Last Posted Date
2021-08-20
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
21
Registration Number
NCT04179461
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

Not Applicable
Active, not recruiting
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Drug: Fluticasone Propionate
First Posted Date
2019-11-20
Last Posted Date
2023-05-09
Lead Sponsor
Tampere University Hospital
Target Recruit Count
88
Registration Number
NCT04171167
Locations
🇫🇮

Tampere University Hospital, Tampere, Finland

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Phase 2
Completed
Conditions
Blepharitis
Interventions
Drug: Placebo
Drug: Fluticasone Propionate
First Posted Date
2019-04-24
Last Posted Date
2023-06-18
Lead Sponsor
Nicox Ophthalmics, Inc.
Target Recruit Count
36
Registration Number
NCT03926026
Locations
🇺🇸

Texan Eye, Austin, Texas, United States

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

First Posted Date
2019-03-20
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
313
Registration Number
NCT03882047

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

First Posted Date
2018-12-20
Last Posted Date
2018-12-20
Lead Sponsor
Claire Daniels
Target Recruit Count
100
Registration Number
NCT03781596
Locations
🇺🇸

Walter Reed National Military Medical Center, Bethesda, Maryland, United States

The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series

Early Phase 1
Completed
Conditions
T1DM
Hypersensitivity
Interventions
Drug: Fluticasone Propionate
First Posted Date
2018-07-20
Last Posted Date
2019-08-13
Lead Sponsor
Assaf-Harofeh Medical Center
Target Recruit Count
13
Registration Number
NCT03594565

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Phase 3
Completed
Conditions
Nasal Polyposis
Interventions
Drug: Fluticasone Propionate
First Posted Date
2018-07-18
Last Posted Date
2020-08-03
Lead Sponsor
Optinose US Inc.
Target Recruit Count
11
Registration Number
NCT03591068
Locations
🇺🇸

University of Colorado SOM, Department of Otolaryngology, Aurora, Colorado, United States

🇺🇸

University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy